Before scaling a biotech strategy, I want to see a legible evidence chain, a realistic operational plan for the next study or assay expansion, and a regulatory path that has been thought about early enough to influence the design work.
Three evaluation axes to compare:
- credibility of the evidence package
- alignment between science and operating plan
- clarity of the regulatory path ahead
Review materials:
- scverse: scverse.org/
A strong starting point for open computational work in modern omics analysis.
- Addgene protocols: addgene.org/protocols/
Practical wet-lab documentation that is genuinely useful for day-to-day work.
- scvi-tools: github.com/scverse/scvi-tools
Open source probabilistic tooling for single-cell and spatial omics work.
Save the strongest examples, scorecards, and decision memos in this folio so future teammates can see what good evaluation looked like at the time.
Keep Exploring
Jump to the author, the parent community or folio, and a few closely related posts.
Related Posts
Three live arguments in biotech that are worth having in public
The central debates are about how much platform optionality to preserve, when to narrow around a lead program, and what evidence threshold deserves clinical acc...
Nina Patel in Biotech Operating Notes · 0 likes · 0 comments
A genuinely useful starter pack for biotech
A helpful biotech starter pack needs one regulatory process guide, one translational science lens, and one open computational toolkit people can actually learn ...
TopicFolio Research in Biotech Operating Notes · 0 likes · 0 comments
The quiet mistakes that slow people down in biotech
The classic mistake is overselling platform breadth before the lead program has earned it. Another is treating regulatory strategy like a writing exercise that ...
TopicFolio Editorial in Biotech Operating Notes · 0 likes · 0 comments
Explore more organized conversations on TopicFolio.